Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population

Archives of Toxicology

Volumn 76, Issue 11, 2002, Pages 643-649

  Kocabaş, Neslihan Aygün ^a   Şardaş, Semra ^a   Cholerton, Suzanne ^b   Daly, Ann K ^b   Karakaya, Ali Esat ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; COMT; CYP1B1; Estrogen; Genetic polymorphisms; Turkish population

Indexed keywords

CARCINOGEN; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1B1; ESTROGEN; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; PREGNANCY; PRIORITY JOURNAL; REPRODUCIBILITY; RISK FACTOR; TURKEY (REPUBLIC); BREAST TUMOR; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0036460764     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-002-0387-x     Document Type: Article

References (34)

1. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M (2002) Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 61:586-594
2. Bailey LR, Roodi N, Dupont WD, Parl FF (1998) Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Adv Brief Cancer Res 58:5038-5041
3. Daly AK, Steen VM, Fairbrother KS, Idle JR (1996) CYP2D6 multiallelism. Methods Enzymol 272:199-210
4. Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843-854
5. Feigelson HS, Henderson BE (1996) Estrogens and breast cancer. Comment Carcinog 17:2279-2284
6. Fritsche E, Brüning T, Jonkmanns C, Ko Y, Bolt HM, Abel J (1999) Detection of Cytochrome P450 1B1 Bfr I polymorphism: Genotype distribution in healthy German individuals and in patients with colorectal carcinoma. Pharmacogenetics 9:405-408
7. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440-3444
8. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1 and COMT: A multigenic study on cancer susceptibility. Cancer Res 59:4870-4875
9. Inoue K, Asao T, Shimada T (2000) Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 30:285-295
10. Kocabaş NA, Karakaya AE, Cholerton S, Şardaş S (2001) Catechol-O-methyltransferase (COMT) genetic polymorphism in a Turkish population. Arch Toxicol 75:407-409
11. Lachman HM, Papolos DF, Saito T, Yu Y, Szumlanski CL, Weinshilbaum RM (1996) Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250
12. Lavigne JA, Helzlsouer KJ, Huang H, Strickland PT, Bell DA, Selmin O, Watson MA, Hoffman S, Comstock GW, Yager JD (1997) An association between the allele coding for a low activity variant of catechol-O-methyltransferase and risk for breast cancer. Adv Brief Cancer Res 57:5493-5497
13. Li JJ, Li SA (1998) Breast cancer: Evidence for xeno-oestrogen involvement in altering its incidence and risk. Pure Appl Chem 70:1713-1723
14. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T (2000) Polymorphism P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 10:343-353
15. Lundström K, Salminen M, Jalanko A, Savolainene R, Ulmanen I (1991) Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 10:181-189
16. Mannistö PT, Ulmanen I, Lundstom K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S (1992) Characteristics of COMT and properties of selective COMT inhibitor. Prog Drug Res 39:291-350
17. Matsui A, Ikeda T, Enomoto K, Hosoda K, Nakashima H, Omae K, Watanabe M, Hibi T, Kitajima M (2000) Progression of human breast cancers to metastatic state is linked to genotypes of catechol-O-methyltransferase. Cancer Lett 150:23-31
18. Millikan RC, Pittman GS, Tse CJ, Duell E, Newman B, Savitz D, Moorman PG, Boissy RJ, Bell DA (1998) Catechol-O-methyl-transferase and breast cancer risk. Carcinogenesis 19:943-1947
19. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A (2001) Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:635-40
20. Özsari H, Atasever L (1994) Cancer Registry Report of Turkey 1993/1994. Turkish Ministry of Health, Ankara, pp 5-6
21. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP (1996) Activation of chemically diverse procarcinogens by cytochrome P450 1B1. Cancer Res 56:2979-2984
22. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gilliam EMJ, Inoue K (1999) Catalytic properties of human P450 1B1 variants. Carcinogenesis 20:1607-1613
23. Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y, Sutter TR (1998) Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19:291-298
24. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, et al (1998) Sequence analysis and homology modeling suggest primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62:573-584
25. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I (1997) Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7:65-71
26. Tenhunen J, Salminen M, Lunstrom K, Kiviluoto T, Savolainene R, Ulmanen I (1994) Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223:1049-1059
27. Thompson PA, Ambrosone C (2000) Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monographs 27:125-134
28. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrose CB (1998) Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 58:2107-2110
29. Toniolo PG (1997) Endogenous estrogens and breast cancer risk: The case for prospective cohort studies. Environ Health Perspect 105:587-592
30. Watanabe J, Shimada T, Gillam EMJ, Ikuta T, Suemasu K, Higaashi Y, Gotoh O, Kawajiri K (2000) Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10:25-33
31. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Ann Rev Pharmacol Toxicol 36:203-232
32. Yim SS, Park SK, Yoo KY, Chung HH, Kang HJ, Ahn SH, Noh DY, Choe KJ, Jang IJ, Shin SG, Strickland PT, Hirvonen A, Kang D (2001) Relationship between the Val158Met polymorphism of catechol-O-methyltransferase and breast cancer. Pharmacogenetics 11:279-288
33. Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, Shu XO, Gao YT (2000) Genetic polymorphism of cytochrome CYP1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9:147-150
34. Zhu BT, Conney AH (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58:2269-2277